Definium Therapeutics (DFTX) Non Operating Investment Income (2025 - 2026)

Definium Therapeutics (DFTX) reported Non Operating Investment Income of -$262000.0 for Q1 2026, down 2720.0% year-over-year from $10000.0 in Q1 2025, and down 397.73% quarter-over-quarter from $88000.0 in Q4 2025.

Definium Therapeutics (DFTX) Non Operating Investment Income (2025 - 2026) Analysis & Trends

Definium Therapeutics (DFTX) has 2 years of Non Operating Investment Income data on file, last reported at -$262000.0 in Q1 2026.

  • Non Operating Investment Income for Q1 2026 came in at -$262000.0, down 2720.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $58000.0 (changed N/A YoY), and the FY2025 annual result was $330000.0, changed N/A from the prior year.
  • Non Operating Investment Income eased to -$262000.0 in Q1 2026 per DFTX's latest filing, from $88000.0 in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at $196000.0 in Q3 2025 and troughed at -$262000.0 in Q1 2026.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 235,807.00
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 230,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Definium Therapeutics 2.46 Bn 2.09 Bn - -262,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -262,000.00
Mar 31, 2026 -262,000.00
Dec 31, 2025 88,000.00
Dec 31, 2025 88,000.00
Sep 30, 2025 196,000.00
Sep 30, 2025 196,000.00
Jun 30, 2025 36,000.00
Jun 30, 2025 36,000.00
Mar 31, 2025 10,000.00
Mar 31, 2025 10,000.00